article thumbnail

3 Count: Notorious Markets 2022

Plagiarism Today

First off today, Chris Cooke at Complete Music Update reports that the United States Trade Representative has released its annual list of “notorious markets” that identifies countries that, according to it, are failing to take adequate action to prevent copyright and other kinds of intellectual property infringement.

Marketing 174
article thumbnail

Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J

LexBlog IP

announced that they reached a settlement and license agreement with Johnson & Johnson regarding AVT04, Alvotech’s proposed biosimilar to STELARA (ustekinumab) in the United States. The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab

LexBlog IP

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

article thumbnail

Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04

LexBlog IP

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech has commercial partners for AVT04 in each of the aforementioned markets. Per the settlement agreement, AVT04 can be marketed in the U.S.,

article thumbnail

Biocon Settles with Janssen, Securing U.S. Market Entry Date for Ustekinumab Biosimilar

JD Supra Law

​​​​​​​On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson (“J&J”) regarding Bmab 1200, Biocon’s proposed biosimilar to STELARA. By: Goodwin

article thumbnail

Celltrion Stelara (Ustekinumab) Settlement With J&J

LexBlog IP

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

article thumbnail

Biocon Settles with Janssen, Securing U.S. Market Entry Date for Ustekinumab Biosimilar

LexBlog IP

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. As part of the settlement, Biocon has agreed to terminate the pending inter partes review of Janssen and J&J’s U.S. Amgen secured a U.S. The post Biocon Settles with Janssen, Securing U.S.